Liu Hong-qin, Wang Dong-mei, Qu Hao, Shi Lin, Huang Li-hua, Feng Chun-ling, Zhang Li-yan, Zhu Wei-bin
Union Stem Cell &Gene Engineering Co., Ltd., Tianjin 300384, China.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2010 May;26(5):456-8.
To prepare and characterize the specific monoclonal antibodies (mAbs) that can recognize the native conformation of HER2 so as to guide the clinical application of Herceptin.
Hybridomas were generated by the fusion with the NS1 myeloma cell and spleen cell, which were from mice immunized by HER2 recombinant protein. After cell fusion, ELISA, Yeast cell base ELISA and immunohistochemistry were used to screening clones respectively.
Eight clones that could react with SK-Br-3 and yeast displaying HER2 were selected from 168 clones which were positive in initial screening by ELISA.
Successfully prepared 8 mAbs that can recognize the native conformation of HER2, which should provide useful reagent for personalized therapy against breast cancer with Herceptin.
制备并鉴定能够识别HER2天然构象的特异性单克隆抗体（mAb），以指导赫赛汀的临床应用。
用HER2重组蛋白免疫小鼠，取其脾细胞与NS1骨髓瘤细胞融合制备杂交瘤。细胞融合后，分别采用ELISA、酵母细胞基础ELISA和免疫组化法筛选克隆。
从ELISA初筛阳性的168个克隆中，筛选出8个能与SK-Br-3及展示HER2的酵母发生反应的克隆。
成功制备出8种能够识别HER2天然构象的单克隆抗体，可为赫赛汀个体化治疗乳腺癌提供有用的试剂。
